<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Asthma Allergy and Lung Biology</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B8DE35C1-BD77-40C7-A617-698BD33A5AB7"><gtr:id>B8DE35C1-BD77-40C7-A617-698BD33A5AB7</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Sutton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1244339E-4070-4346-842C-EAB736E8A261"><gtr:id>1244339E-4070-4346-842C-EAB736E8A261</gtr:id><gtr:firstName>Tak</gtr:firstName><gtr:surname>Lee</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/80CC8B4C-7103-471D-AB94-884EF0AAFBB9"><gtr:id>80CC8B4C-7103-471D-AB94-884EF0AAFBB9</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>McDonnell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/85F4F906-8476-4AEC-9B1B-818D2496249B"><gtr:id>85F4F906-8476-4AEC-9B1B-818D2496249B</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>R</gtr:otherNames><gtr:surname>Durham</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C68DCAD6-AB77-43CC-AEAF-45EB93348FA8"><gtr:id>C68DCAD6-AB77-43CC-AEAF-45EB93348FA8</gtr:id><gtr:firstName>Hannah</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Gould</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9805965"><gtr:id>2BF541DF-F042-4AD6-B64F-DF0AEB1798D3</gtr:id><gtr:title>Molecular mechanisms and interventions in allergy and asthma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9805965</gtr:grantReference><gtr:abstractText>The health and economic burden of allergic diseases, including asthma, on the nation emphasizes the importance of research that tries to understand the mechanisms of these disorders. Allergy is caused by the presence of a specific antibody in the body, named IgE. The current research looks at ways in which the body makes this substance and how to switch it off. In asthma, one of the commonest allergic conditions, previous evidence has suggested that inflammation in the bronchial tubes in the lungs of patients play an essential role in perpetuating and causing severe disease. The proposed research analyses the control for the production of a number of substances, named cytokines, which are believed to be central to orchestrating bronchial inflammation in asthma. The results of the proposed work may provide new ideas on how to develop strategies for treatment of this common condition. Tak Lee (lead applicant) is the National Asthma Campaign Professor. The Charity can therefore help to publicize, in conjunction with the MRC, discoveries originating from the proposed research to its extensive lay membership through its news letters and to the wider public via its well established contacts in the media, whenever appropriate.</gtr:abstractText><gtr:technicalSummary>IgE plays a critical role in the pathogenesis of asthma and allergic disease, not only through the sensitisation of mast cells and basophils through binding of IgE to the high-affinity IgE receptor FceRI, which provides a mechanism for acute exacerbation of asthma on allergen exposure, but also by binding of IgE to the low-affinity IgE receptor (CD23) on langerhans cells and monocytes. Thus, IgE is also involved in allergen capture, processing and presentation. It is therefore central to investigate the mechanisms regulating IgE synthesis and the interaction of IgE with its receptors. Glucocorticoids remain the cornerstone of therapy for asthma and allergic disease. One of the principal actions of these drugs is to inhibit the production of cytokines by Th2 cells such IL-4 and IL-13 that control IgE synthesis. 


The overall strategy of our Cooperative group has always been to elucidate the molecular mechanisms of allergic disease and to identify new therapeutic targets. Creation of the group has permitted established groups of investigators to focus collectively and synergistically on a number of critical and unresolved issues in allergic disease. Significant contributions have been made to each of the original objectives identified approximately four years ago and substantial additional funding has been attracted. The work proposed in our renewal application is particularly timely because the molecular and other technologies developed in our earlier work can be used to progress proposed studies in an expeditious manner. Our renewal application addresses : (a) structural studies of protein-protein interactions of the IgE network; (b) the role of CD23 in the commitment of B cells to IgE synthesis; (c) domain folding in IgE; (d) molecular structure recognition and regulation of IgE; (e) localised IgE switching of the bronchial mucosa of intrinsic asthmatics; (f) the mechanisms of glucocorticoid action on IL-4 and IL-13; Th2 cytokines that regulate IgE production.</gtr:technicalSummary><gtr:fund><gtr:end>2009-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1998-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>303965</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Heart &amp; Lung Institute (NHLI)</gtr:department><gtr:description>MRC Co-operative collaborations</gtr:description><gtr:id>FEB89F3A-556C-4172-B3F2-47AC94123393</gtr:id><gtr:impact>See section 2</gtr:impact><gtr:outcomeId>C6D3F5A848B-1</gtr:outcomeId><gtr:partnerContribution>Collaboration between King's and Imperial Colleges increased (1) The patient database for our clinical studies on asthma and allergy (2) The range of laboratory expertise, especially with animal models of asthma</gtr:partnerContribution><gtr:piContribution>The co-opertaive funding encouraged numerous colaborations between resrachers at King's and |imperial Colleges, leading ultimately in a successful application to the MRC to found the MRC Centre in Allergic Mechanisms of Asthma. Ther output of research from these collaborations has been vast (see publication list).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>458249</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC grant</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>977CB55D-2BCF-46DC-832C-668D1574AC8E</gtr:id><gtr:outcomeId>qNe8GmQJKJH0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8AA2AA0B-4A07-458D-BD7B-DD6920009C99</gtr:id><gtr:title>The ADMIT series--issues in inhalation therapy. 3) Mild persistent asthma: the case for inhaled corticosteroid therapy.</gtr:title><gtr:parentPublicationTitle>Primary care respiratory journal : journal of the General Practice Airways Group</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c71c2e38e2c4a66ed88e03590625cec6"><gtr:id>c71c2e38e2c4a66ed88e03590625cec6</gtr:id><gtr:otherNames>Corrigan CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-4418</gtr:issn><gtr:outcomeId>8B20F7FD3A4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A053E923-C3A6-47DE-8656-7C24EF948976</gtr:id><gtr:title>Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe6b5092222fe541edc247496289b7dd"><gtr:id>fe6b5092222fe541edc247496289b7dd</gtr:id><gtr:otherNames>Loke TK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>BF33168F986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61CF8D78-306A-48B8-B403-76B3465BACDC</gtr:id><gtr:title>Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases.</gtr:title><gtr:parentPublicationTitle>Clinical allergy and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89bf7e14794f9e9e16143bf1815781ed"><gtr:id>89bf7e14794f9e9e16143bf1815781ed</gtr:id><gtr:otherNames>Calder?n MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1075-7910</gtr:issn><gtr:outcomeId>51E9A39024F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>759F2E92-92A4-4048-B137-1CE474ABDEE2</gtr:id><gtr:title>The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea5e4c8d96fbfc7afbca0a5d4b5125d9"><gtr:id>ea5e4c8d96fbfc7afbca0a5d4b5125d9</gtr:id><gtr:otherNames>Bousquet PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>9CAEA1660C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8ADC31B-F900-4163-B718-64828F9C5C07</gtr:id><gtr:title>Regulatory T cells and allergic disease.</gtr:title><gtr:parentPublicationTitle>Inflammation &amp; allergy drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/977a6e49804f262c5b65378eb3fdccfb"><gtr:id>977a6e49804f262c5b65378eb3fdccfb</gtr:id><gtr:otherNames>Nouri-Aria KT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1871-5281</gtr:issn><gtr:outcomeId>C7CD5E0FB24</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18FA127C-1BA1-4F35-8247-5CD89CB64C97</gtr:id><gtr:title>Tradition and innovation: finding the right balance.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91ef542f164b4e5636afc9051893a45c"><gtr:id>91ef542f164b4e5636afc9051893a45c</gtr:id><gtr:otherNames>Durham SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>74E4198D948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64F722A7-9D50-43BA-8380-1D64ACDFB3FB</gtr:id><gtr:title>Effects of a reversible beta-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bb4e1304e7bf802578aea7bcc178ca4"><gtr:id>5bb4e1304e7bf802578aea7bcc178ca4</gtr:id><gtr:otherNames>Erin EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>E3E2F308722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>519EB7B4-ABAE-4848-96DB-4C4609CC5464</gtr:id><gtr:title>Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life.</gtr:title><gtr:parentPublicationTitle>Allergy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fb0d5b8a7597f6f730fa62bbd1b2775"><gtr:id>3fb0d5b8a7597f6f730fa62bbd1b2775</gtr:id><gtr:otherNames>Fr?lund L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0105-4538</gtr:issn><gtr:outcomeId>7E6D7F2F08C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6B4B8C6-F051-43AB-8A70-973516BFF7B2</gtr:id><gtr:title>Allergen immunotherapy (desensitisation) for allergic diseases.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91ef542f164b4e5636afc9051893a45c"><gtr:id>91ef542f164b4e5636afc9051893a45c</gtr:id><gtr:otherNames>Durham SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>DEF5A869025</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A007816-04AD-475E-92F0-47F25CCC5BE2</gtr:id><gtr:title>BSACI guidelines for the management of drug allergy.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b73e01f0a849395586da3fdedf61447"><gtr:id>2b73e01f0a849395586da3fdedf61447</gtr:id><gtr:otherNames>Mirakian R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>803F54E88D1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>480B6529-3BB0-455F-BEC1-27825443D654</gtr:id><gtr:title>Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f26da72ee37dfc6742069ea3f6c9aafe"><gtr:id>f26da72ee37dfc6742069ea3f6c9aafe</gtr:id><gtr:otherNames>Varga EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>D8D3E80676B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BF0D8C6-54C1-4537-87F3-C9CBA6D4753D</gtr:id><gtr:title>Allergic rhinitis and its impact on asthma update: allergen immunotherapy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1e8117ff5f9a27d35abe71afd99cd8a"><gtr:id>a1e8117ff5f9a27d35abe71afd99cd8a</gtr:id><gtr:otherNames>Passalacqua G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>A9EE8E1B192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA62346F-3F87-4F17-BF2A-44E9ECCE6341</gtr:id><gtr:title>IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c46e2ecdbdcf081c5e7884ac05702bb5"><gtr:id>c46e2ecdbdcf081c5e7884ac05702bb5</gtr:id><gtr:otherNames>Kurowska-Stolarska M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>F6A0B44346D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA2F9C75-7D19-4085-A619-44319CC00BEE</gtr:id><gtr:title>Sublingual immunotherapy: what have we learnt from the 'big trials'?</gtr:title><gtr:parentPublicationTitle>Current opinion in allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91ef542f164b4e5636afc9051893a45c"><gtr:id>91ef542f164b4e5636afc9051893a45c</gtr:id><gtr:otherNames>Durham SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1473-6322</gtr:issn><gtr:outcomeId>ED240F19B56</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD199BED-A4E9-4BA3-94D2-DB36805D0861</gtr:id><gtr:title>The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team.</gtr:title><gtr:parentPublicationTitle>Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0a3d9c0897ca34c341f4497f41c4305"><gtr:id>a0a3d9c0897ca34c341f4497f41c4305</gtr:id><gtr:otherNames>Crompton GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0954-6111</gtr:issn><gtr:outcomeId>5D96D69EC47</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30C78219-3BE3-4895-82E2-969B0CA93BA4</gtr:id><gtr:title>Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/466033ad49019ef0f32ed5242943d919"><gtr:id>466033ad49019ef0f32ed5242943d919</gtr:id><gtr:otherNames>Ying S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>4496A3BC1FF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E299223-771B-41D0-B6D9-96921B8CF5C5</gtr:id><gtr:title>Immunologic responses to subcutaneous allergen immunotherapy.</gtr:title><gtr:parentPublicationTitle>Clinical allergy and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec44db22bfb4a33f6c40a4ae949b6ae2"><gtr:id>ec44db22bfb4a33f6c40a4ae949b6ae2</gtr:id><gtr:otherNames>Till SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1075-7910</gtr:issn><gtr:outcomeId>61D380A21E0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>663DB73A-5860-499E-ABE0-E4E511454E0E</gtr:id><gtr:title>Inhaler choice and inhalation technique: key factors for asthma control.</gtr:title><gtr:parentPublicationTitle>Primary care respiratory journal : journal of the General Practice Airways Group</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e7f28386436b2d989df53f372f698e7"><gtr:id>1e7f28386436b2d989df53f372f698e7</gtr:id><gtr:otherNames>Lavorini F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-4418</gtr:issn><gtr:outcomeId>00309098828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B97AD228-1E2B-4328-AD6F-71A817E3C85F</gtr:id><gtr:title>Seasonal changes in suppressive capacity of CD4+ CD25+ T cells from patients with hayfever are allergen-specific and may result in part from expansion of effector T cells among the CD25+ population.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2477b5d7e508836405c9470841c9452e"><gtr:id>2477b5d7e508836405c9470841c9452e</gtr:id><gtr:otherNames>Anderson AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>7EFBA2D58D6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82D50E35-333B-478E-90CD-F7C14C6FE609</gtr:id><gtr:title>Rhinitis with negative skin tests and absent serum allergen-specific IgE: more evidence for local IgE?</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e99419069b860ea088ea32ca81cb26b1"><gtr:id>e99419069b860ea088ea32ca81cb26b1</gtr:id><gtr:otherNames>James LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>C446FD8DAEB</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9805965</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>